Just a single breath of a vaccine mist can offer strong immune protection from COOVID-19, CanSino, a vaccine maker announced in a news release over the weekend.
Business Insider reported that regulators in China approved a COVID-19 vaccine mist for use as a booster dose, making it the first substitute for injectable vaccines used during this pandemic.
The inhaled vaccine has the same ingredients as the injections used in China, although a nebulizer machine has turned it from "liquid into an aerosol spray."
Similar to the vaccines against COVID-19 used in the United States, this formulation of CanSino contains pieces of genetic materials, and thus, the body can recognize the virus.
ALSO READ: 'Worrying' Mutation Detected in the UK
A Single-Dose Shot
Whereas Moderna and Pfizer vaccines directly introduced the material, the CanSino vaccine uses a "harmless version" of a common virus to carry information about the COVID-19 virus.
This single-dose shot of the CanSino vaccine is approximately 92 percent effective when it comes to preventing severe infection because of COVID-19, and around 58 percent effective in terms of total illness prevention, the data reported by the World Health Organization revealed.
Clinical trials of the mist as a booster, after a single injected dose of the vaccinee, revealed it was roughly as efficient as the two-dose vaccine that's commonly used abroad, as well as in Asia.
The Nasal mist may strengthen protection in the lining of the upper airways and the nose, where the virus usually enters the body, the company's press statement specified.
'Mistable' COVID-19 Vaccine
Previously, according to a related ScienceAlert report, other vaccines have been repackaged, also as mist, like the FluMist intranasal vaccine seen in pediatricians' clinics every flu season.
Essentially, the inhaled vaccine offers a needle-free alternative for children and adults alike, although evidence from past flu seasons has shown that the mist does not always achieve the same efficacy level, as a shot.
Only time will tell if the so-called "mistable" vaccine against COVID-19 offers adequate booster protection to be authorized and widely distributed in other countries.
Inhaled Vaccine as a Booster Dose
CanSino Biologist Inc. or CanSinoBIO announced that the National Medical Products Administration of China has granted the company the authorization and approval for its Recombinant COVID-19 vaccine for inhalation to be used as a booster shot.
As the statement indicates, the company also said that using the same adenovirus vector technological platform as the intramuscular version Convidecia, "Convidecia Air offers a non-invasive option" that's utilizing a nebulizer to change liquid into an aerosol for annihilation through the mouth.
Convidecia Air is a needle-free vaccine. It can effectively generate comprehensive immune protection in response to COVID-19 infection after only a single breath.
Aim to Make the Vaccine Accessible Worldwide
The company received the authorization for its clinical trial application for Convidecia Air in March last year. Research published in The Lancet specified that Convidecia Air can generate strong cellular, mucosal, and humoral immunity to attain triple protection and efficiently manage the infection and transmission of the virus.
At present, CanSinoBIO has gained steady production of different innovative vaccines and established a worldwide supply chain, with a goal of continuing to make quality vaccine products more accessible to the population all over the world.
Related information about CanSinoBIO's related single-shot vaccine is shown on CGTN's YouTube video below:
RELATED ARTICLE: 'Long COVID' Symptoms Could Be Seen in Patients' Eyes, According to Doctors
Check out more news and information on COVID-19 and Vaccines in Science Times.